Beginning Feb. 2, 2026, medical technology news and analysis will be integrated into BioWorld, where curated coverage will continue as part of BioWorld’s core reporting.
Liver fibrosis in the course of metabolic dysfunction-associated steatohepatitis could be significantly reduced using CAR T-cells generated in vivo. Scientists at the Icahn School of Medicine at Mount Sinai have developed an experimental cell therapy that eliminates only one type of liver cell, the stellate cells that express fibroblast activation protein alpha. This strategy not only reduced fibrosis but also reversed liver damage.
Regulatory snapshots, including global drug submissions and approvals, and other regulatory decisions and designations: Almirall, Elevar, Summit, Tenpoint.
Biopharma happenings, including deals and partnerships, and other news in brief: Alvotech, Bayer, Chia Tai Feng Hai, Formation Bio, Regeneron, Repare, Xeno.
After reaching their peaks in late November, both the BioWorld Drug Developers Index and the Nasdaq Biotechnology Index finished the year slightly down from those highs.
RSS
